NORWALK, Conn., Nov. 22, 2016 /PRNewswire/ -- Mederi Therapeutics Inc., manufacturers of Stretta Therapy for gastroesophageal reflux disease (GERD), announced the publication of a case series demonstrating the viability of Stretta Therapy as a treatment for chronic GERD after a Laparoscopic Sleeve Gastrectomy (LSG). It was published in the November issue of Bariatric Times, a peer-reviewed publication.
The article, "A Case Series of GERD in the Bariatric Patient: Stretta Therapy as a Treatment Option," analyzed results of four LSG patients that received Stretta to treat chronic GERD at Duke University Health System. Authored by A. Daniel Guerron, MD, Assistant Professor of Surgery and Dana Portenier, MD, Chief, Division of Metabolic and Weight Loss Surgery, Co-Director, Minimally Invasive and Bariatric Surgery Fellowship, and Assistant Professor of Surgery, the article outlined the challenges involved with these patients, and why Stretta has emerged as a favorable treatment strategy. Noting the growing popularity of the LSG procedure for weight loss, the authors explained why the less invasive LSG is attractive to patients but noted that LSG does not resolve GERD symptoms as consistently as gastric bypass. GERD after LSG can result in the need for a revisional surgery. And although more research is needed on the role of LSG in GERD, there is a need for a non-surgical option for patients who experience GERD after a bariatric procedure.